Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Achhra, Amit C ^a   Boyd, Mark A ^a   Law, Matthew G ^a   Matthews, Gail V ^a   Kelleher, Anthony D ^a   Cooper, David A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYCLOHEXANE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; AUSTRALIA; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG ACTIVITY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; POPULATION RESEARCH; ANALOGS AND DERIVATIVES; MIDDLE AGED;

ADENINE; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; DIDEOXYNUCLEOSIDES; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RITONAVIR; TRIAZOLES;

EID: 84903388349     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099530     Document Type: Article

References (44)

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402.
2. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, et al. (2011) Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 25: 1289-1298.
3. Costagliola D, Lang S, Mary-Krause M, Boccara F (2010) Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep 7: 127-133.
4. Hill A, Sawyer W (2009) Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med 10: 527-535.
5. Calza L (2012) Renal toxicity associated with antiretroviral therapy. HIV Clin Trials 13: 189-211.
6. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, et al. (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76: 1403-1409.
7. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, et al. (2004) Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1: e19.
8. Achhra AC, Boyd MA (2013) Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther 10: 33.
9. SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, et al. (2013) Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard firstline ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 381: 2091-2099.
10. Paton N, Kityo C, Hoppe A, Hakim J, van Oosterhout J, et al. (2013) A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia.
11. Cahn P, The GARDEL Study Group. (2013) Dual therapy with Lopinavir/Ritonavir (LPV/r) and Lamivudine (3TC) is non-inferior to standard triple drug therapy in Naïve HIV-1 infected subjects: 48-week results of the GARDEL Study. 14th European AIDS Conference Brussels, Belgium.
12. Stanford University. HIV Drug Resistance Database. HIV Drug Resistance Database. Available: http://hivdb.stanford.edu/. Accessed 25 June 2013.
13. Tu E, Swenson LC, Land S, Pett S, Emery S, et al. (2013) Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study. J Clin Microbiol 51: 2063-2071.
14. Australian HIV Observational Database (2002) Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 3: 28-36.
15. Margolis D, Brinson C, Eron J, Richmond G, LeBlanc R, et al. (2014) 744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results [Abstract 91LB]. 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
16. Cotte L, Durant J, Brochier C, et al (2013) Safety and efficacy of a Maraviroc-Raltegravir combination following a 6 month induction phase with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in naïve HIV-1 infected patients with CCR5 Virus: interim analysis of the No Nuc No Boost study [Abstract WEPE511]. IAS 2013. Kaula Lumpur, Malaysia.
17. Ward DJ, O'Neil D.J (2013) Nucleoside-sparing antiretroviral regimens in clinical practice. [Abstract H-659]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver USA.
18. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, et al. (2012) A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clinical Trials 13: 119-130.
19. Carey D, Pett SL, Bloch M, Wand H, MacRae K, et al. (2012) A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. J Acquir Immune Defic Syndr 60: 143-149.
20. Cordery DV, Hesse K, Amin J, Cooper DA (2010) Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther 15: 1035-1038.
21. Allavena C, Mounoury O, Rodallec A, Reliquet V, Billaud E, et al. (2009) Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population. HIV Clin Trials 10: 337-340.
22. Gupta S, Lataillade M, Farber S, Kozal MJ (2009) Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants. J Int Assoc Physicians AIDS Care 8: 87-92.
23. Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, et al. (2009) Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 199: 866-871.
24. Mills A, Mildvan D, Podzamczer D, Fatkenheuer G, Leal M, et al. (2013) Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. J Acquir Immune Defic Syndr 62: 164-170.
25. Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, et al. (2013) Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother 68: 1364-1372.
26. Calin R, Valantin M, Simon A, Paris L, Tubiana R, et al. (2013) Raltegravir/etravirine dual therapy as a virologically safe treatment option in suppressed HIV-1-infected patients without previous NNRTI failure. 7th International AIDS Society Conference on HIV Pathogenesis Treatment and Prevention. Kuala Lumpur, Malaysia.
27. Monteiro P, Perez I, Laguno M, Martinez-Rebollar M, Gonzalez-Cordon A, et al. (2014) Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother 69: 742-8.
28. Imaz A, Llibre JM, Mora M, Mateo G, Camacho A, et al. (2011) Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. [Erratum appears in J Antimicrob Chemother. 2011 Sep; 66(9): 2194]. J Antimicrob Chemother 66: 358-362.
29. Nozza S, Galli L, Bigoloni A, Nicola G, Pogliaghi M, et al. (2011) Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. J Acquir Immune Defic Syndr 56: e113-115.
30. Tashima K SL, Andrade A, et al (2013) Omitting NRTI from ARV regimens is not inferior to adding NRTI in treatment-experienced HIV+ subjects failing a protease inhibitor regimen: the ACTG OPTIONS study [Abstract 153LB]. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia, USA.
31. Bedimo R, Drechsler H, Turner D, Moore T, Ghormley J, et al. (2011) RADAR study: Raltegravir combined with boosted Darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Rome.
32. Ofotokun I, Sheth AN, Sanford SE, Easley KA, Shenvi N, et al. (2012) A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses 28: 1196-1206.
33. Jansen A, Colbers EPH, van der Ven A, Richter C, Rockstroh JK, et al. (2013) Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. HIV Medicine 14: 449-452.
34. Casado JL, de la Calle C, del Palacio M, Perez-Elias MJ, Moreno A, et al. (2013) Short communication: lamivudine plus a boosted-protease inhibitor as simplification strategy in HIV-infected patients: proof of concept. AIDS Res Hum Retroviruses 29: 588-591.
35. Taiwo B, Murphy RL, Katlama C (2010) Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. Drugs 70: 1629-1642.
36. Imaz A, del Saz SV, Ribas MA, Curran A, Caballero E, et al. (2009) Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. [Erratum appears in J Acquir Immune Defic Syndr. 2011 Nov 1;58(3): e102]. J Acquir Immune Defic Syndr 52: 382-386.
37. Raffi F, Babiker A, Richert L, Molina J, George E, et al. (2014) First-Line Raltegravir (RAL) + Darunavir/Ritonavir (DRV/r) is Non-inferior to Tenofovir/Emtricitabine (TDF/FTC) + DRV/r: The NEAT 001/ANRS 143 Randomised Trial [Abstract 84LB]. 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
38. Katlama C, Assoumou L, Valantin MA, Soulie C, Duvivier C, et al. (2014) Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother.
39. Achenbach CJ, Darin KM, Murphy RL, Katlama C (2011) Atazanavir/ritonavir- based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol 6: 157-177.
40. Squires KE, Young B, DeJesus E, Bellos N, Murphy D, et al. (2012) ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials 13: 233-244.
41. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, et al. (2011) Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 25: 2113-2122.
42. Carr A, Hoy J, Pozniak A (2012) The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior? PLoS Med 9: e1001240.
43. Orrell C, Felizarta F, Nell A, Kakuda T, Lavreys L, et al (2013): Etravirine 200 mg twice daily combined with atazanavir/ritonavir 300/100 mg or 400/100 mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial IAS. Kaula Lumpur, Malaysia.
44. Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, et al. (2011) Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 25: 2249-2258.